Executive management update & unaudited FY26 results
| Stock | Somnomed Ltd (SOM.ASX) |
|---|---|
| Release Time | 27 Jul 2026, 6:39 p.m. |
| Price Sensitive | Yes |
Somnomed Ltd. Executive Update and FY26 Results
- Amrita Blickstead steps down as Co-CEO
- Karen Borg assumes role of CEO
- FY26 unaudited revenue: $114M-$115M
- Targeting high single-digit revenue growth in FY27
- Launch of VirtusTM for OSA and sleep bruxism
Somnomed Ltd. announced that Ms. Amrita Blickstead has stepped down as Co-CEO, with Ms. Karen Borg taking over as CEO. The company reported unaudited FY26 revenue of between $114 million and $115 million, below the latest guidance of $119 million to $126 million, due to market dynamics in Europe and the appreciation of the Australian dollar. The company achieved double-digit growth in EBITDA by maintaining a disciplined approach to cost and capital management. Somnomed also launched VirtusTM, a therapy for patients with OSA and coexisting sleep bruxism. The company targets high single-digit revenue growth in FY27, with guidance to be issued alongside the FY26 year-end results.
FY26 revenue: $114M-$115M, FY27 revenue growth: high single-digit
Somnomed targets high single-digit revenue growth in FY27, with FY27 guidance to be issued on or around 28 August 2026.